Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

Anacor PharmaceuticalsMay 5 2012

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will be presenting clinical data on its lead compounds, tavaborole and AN2728, at the following upcoming medical meetings:

“Safety and Efficacy of AN2728 and AN2898 Ointments in a Phase 2a Bilateral Study of Mild-to-Moderate Atopic Dermatitis”

• 72nd Society for Investigative Dermatology Annual Meeting - Thursday, May 10, 2012
  • "Safety and Efficacy of AN2728 and AN2898 Ointments in a Phase 2a Bilateral Study of Mild-to-Moderate Atopic Dermatitis"
• 9th Australasian Society for Dermatology Research Conference - Tuesday, May 22, 2012
  • "Boron-based AN2728 and AN2898 Ointments Demonstrate Safety and Efficacy in a Phase 2a Bilateral Study of Mild-to-Moderate Atopic Dermatitis"
• American Podiatric Medical Association 2012 Annual Scientific Meeting - The National - Friday, August 17, 2012
  • "Safety and Efficacy of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule, in Phase 2 Trials for the Topical Treatment of Toenail Onychomycosis"
• American Academy of Dermatology Summer Academy Meeting - Saturday August 18, 2012
  • "Local Tolerability of AN2728 Topical Ointment, 2% in Sensitive Skin Areas"